Ipamorelin vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | Ipamorelin | Liraglutide |
|---|---|---|
| Mechanism | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |
What They Have in Common
Both Ipamorelin and Liraglutide are commonly used for: